Physician profile
Jung E Chan
NPI 1497731152
$1,815.17
in general payments reported to CMS, 2019-2025
12 companies · $864 in 2025
The $864 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $155 · 2021: $31.22 · 2022: $211 · 2023: $162 · 2024: $256 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739 · Travel and Lodging: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.63 |
| Travel and Lodging | $543.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $871.68 | 2019-2025 | Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $211.11 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $132.64 | 2020-2024 | Precision 7, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $121.52 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $113.08 | 2022-2025 | Miebo, Xiidra, Infuse |
| Glaukos Corporation | $112.71 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $63.74 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $56.82 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $49.32 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $30.05 | 2025 | |
| Sight Sciences, INC. | $26.56 | 2022 | |
| Allergan, INC. | $25.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jung Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.